Revumenib
Syndax Pharma
['revumenib', 'augment,trial', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders)', 'augment,data', 'hydroxyurea', 'aml,(-streamline),(-seamless),(-kamloops),(-dreamlike)', 'augment-101', 'leukemia', 'myeloid', '2019', 'sndx-5613']
results of phase 1 augment-101 trial show that inhibiting menin-kmt2a with revumenib is a successful way to treat acute leukemia with kmt2ar (mllr) or mnpm1. ghayas c. issa, md #ash22 #amlsm #aml 
HealthTree for AML is a united community of AML patients, caregivers & medical professionals that provides support, education & tools to accelerate a cure